Search
Foslevcromakalim
go.drugbank.com/drugs/DB21500ExperimentalThe usage of the INN stem '-kalim' in the name indicates that Foslevcromakalim is a potassium channel activator, antihypertensive. Foslevcromakalim has a monoisotopic molecular weight of 366.1 Da.
Safimaltib
go.drugbank.com/drugs/DB21528InvestigationalSafimaltib is under investigation in clinical trial NCT06788509 (A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring).
Izuforant
go.drugbank.com/drugs/DB21571ExperimentalThe usage of the INN stem '-forant' in the name indicates that Izuforant is a histamine H4 receptor antagonist. Izuforant has a monoisotopic molecular weight of 333.03 Da.
Inixaciclib
go.drugbank.com/drugs/DB21584ExperimentalThe usage of the INN stem '-ciclib' in the name indicates that Inixaciclib is a cyclin dependant kinase inhibitor. Inixaciclib has a monoisotopic molecular weight of 480.24 Da.
Monzosertib
go.drugbank.com/drugs/DB21619InvestigationalThe usage of the INN stem '-sertib' in the name indicates that Monzosertib is a serine/threonine kinase inhibitor. Monzosertib has a monoisotopic molecular weight of 465.16 Da.
Votoplam
go.drugbank.com/drugs/DB21645InvestigationalThe usage of the INN stem '-plam' in the name indicates that Votoplam is a SMN2 gene splicing modulator. Votoplam has a monoisotopic molecular weight of 419.22 Da.
Tigemocoxib
go.drugbank.com/drugs/DB21699ExperimentalThe usage of the INN stem '-coxib' in the name indicates that Tigemocoxib is a selective cyclo-oxygenase inhibitor. Tigemocoxib has a monoisotopic molecular weight of 334.06 Da.
[Methyltelluro]Acetate
go.drugbank.com/drugs/DB01918ExperimentalThese are organic compounds containing an oxoanion. This medication targets the protein monomeric sarcosine oxidase.
Bacteroides thetaiotaomicron
go.drugbank.com/drugs/DB17879InvestigationalDeveloped by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]
CYNK-101
go.drugbank.com/drugs/DB18637InvestigationalCYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).